OXiMAb-24A

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameOXiMAb-24A
Drug Alias NameAnti-B cell monoclonal antibody (OXiGENE)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionB-lymphocyte inhibitorsImmunosuppressants
TargetsUpdating
Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOncotelic Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncotelic Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A